PASSAGE BIO, INC. Amortization of Debt Discount (Premium)
PASSAGE BIO, INC. (PASG) reported Amortization of Debt Discount (Premium) of $129.00 thousand for the 12-month period ending 2025-12-31, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-09-03
- PASSAGE BIO, INC. amortization of debt discount (premium) for the quarter ending 2025-12-31 was $0.00.
- PASSAGE BIO, INC. amortization of debt discount (premium) for the quarter ending 2025-09-30 was $0.00.
- PASSAGE BIO, INC. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $0.00.
- PASSAGE BIO, INC. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $129.00K.
- PASSAGE BIO, INC. amortization of debt discount (premium) for fiscal 2023 was -$2.04M, a 363.39% decline from fiscal 2022.
- PASSAGE BIO, INC. amortization of debt discount (premium) for fiscal 2022 was $773.00K, a 72.17% decline from fiscal 2021.
- PASSAGE BIO, INC. amortization of debt discount (premium) for fiscal 2021 was $2.78M, a 338.86% increase from fiscal 2020.
- PASSAGE BIO, INC. amortization of debt discount (premium) for fiscal 2020 was $633.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $0.00 derived: sum of 2 quarters · filed 2026-09-03 | $0.00 derived: sum of 3 quarters · filed 2026-09-03 | $129.00K S-4/A · filed 2026-09-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-09-03 | $129.00K 10-Q · filed 2025-11-10 | -$236.00K derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $0.00 derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | $129.00K S-4/A · filed 2026-09-03 | -$236.00K derived: sum of 3 quarters · filed 2026-09-03 | -$657.00K derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | $129.00K S-4 · filed 2026-07-21 | -$236.00K derived: sum of 2 quarters · filed 2026-09-03 | -$657.00K derived: sum of 3 quarters · filed 2026-09-03 | -$954.00K derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | -$365.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$786.00K derived: sum of 2 quarters · filed 2026-09-03 | -$1.08M derived: sum of 3 quarters · filed 2026-09-03 | -$1.53M S-4/A · filed 2026-09-03 |
| 2024-09-30 | -$421.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$718.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.16M 10-Q · filed 2025-11-10 | -$2.01M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$297.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$741.00K 10-Q · filed 2025-08-12 | -$1.59M derived: sum of 3 quarters · filed 2025-08-12 | -$1.91M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$444.00K 10-Q · filed 2025-05-13 | -$1.29M derived: sum of 2 quarters · filed 2025-05-13 | -$1.61M derived: sum of 3 quarters · filed 2025-05-13 | -$2.38M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$848.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$1.17M derived: sum of 2 quarters · filed 2025-03-04 | -$1.94M derived: sum of 3 quarters · filed 2025-03-04 | -$2.04M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$319.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.09M derived: sum of 2 quarters · filed 2024-11-13 | -$1.19M 10-Q · filed 2024-11-13 | -$1.62M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$771.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$869.00K 10-Q · filed 2024-08-08 | -$1.30M derived: sum of 3 quarters · filed 2024-08-08 | -$1.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$98.00K 10-Q · filed 2024-05-14 | -$531.00K derived: sum of 2 quarters · filed 2024-05-14 | -$476.00K derived: sum of 3 quarters · filed 2024-05-14 | -$200.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | -$378.00K derived: sum of 2 quarters · filed 2024-03-04 | -$102.00K derived: sum of 3 quarters · filed 2024-03-04 | $773.00K 10-K · filed 2024-03-04 |
| 2022-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $331.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.21M 10-Q · filed 2023-11-13 | $1.75M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.15M 10-Q · filed 2023-08-07 | $1.69M derived: sum of 3 quarters · filed 2023-08-07 | $2.58M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $875.00K 10-Q · filed 2023-05-11 | $1.42M derived: sum of 2 quarters · filed 2023-05-11 | $2.31M derived: sum of 3 quarters · filed 2023-05-11 | $2.81M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $543.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $1.43M derived: sum of 2 quarters · filed 2023-03-06 | $1.93M derived: sum of 3 quarters · filed 2023-03-06 | $2.78M 10-K · filed 2023-03-06 |
| 2021-09-30 | $889.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.39M derived: sum of 2 quarters · filed 2022-11-10 | $2.23M 10-Q · filed 2022-11-10 | $2.82M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.35M 10-Q · filed 2022-08-04 | $1.93M derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $848.00K 10-Q · filed 2022-05-16 | $1.43M derived: sum of 2 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $586.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $633.00K 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $47.00K 10-Q · filed 2021-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |